ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND CYTARABINE

1 . A pharmaceutical combination comprising an antibody specifically recognizing CD38 and at least cytarabine, wherein said antibody is capable of killing a CD38 + cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

2 . The combination of claim 1 , wherein said antibody is a humanized antibody.

3 . The combination of claim 2 wherein said antibody comprises one or more complementarity-determining region having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 and 81.

4 . The combination of claim 3 wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 13, 81, and 15, and wherein said light chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 16, 17, and 18.

5 . The combination of claim 3 wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 25, 26, and 27, and wherein said light chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 28, 29, and 30.

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . The combination of claim 3 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has an amino acid sequence represented by SEQ ID NO: 66, and wherein said light chain has an amino acid sequence selected from the group consisting of SEQ ID NOS: 62 and 64.

12 . The combination of claim 3 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has an amino acid sequence represented by SEQ ID NO: 72, and wherein said light chain has an amino acid sequence selected from the group consisting of SEQ ID NOS: 68 and 70.

13 . The combination of claim 3 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has at least about 90% sequence homology with an amino acid sequence represented by SEQ ID NO: 66, and wherein said light chain has at least 90% sequence homology with an amino acid sequence selected from the group consisting of SEQ ID NOS: 62 and 64.

14 . The combination of claim 3 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has at least about 90% sequence homology with an amino acid sequence represented by SEQ ID NO: 72, and wherein said light chain has at least about 90% sequence homology with an amino acid sequence selected from the group consisting of SEQ ID NOS: 68 and 70.

15 . The combination of claim 3 , wherein said antibody comprises the CDRs of an antibody produced by a hybridoma cell line having a deposit number selected from the group consisting of PTA-7667, PTA-7669, PTA-7670, PTA-7666, PTA-7668 and PTA-7671.

16 . A method for treating cancer in a subject, the method comprising administering the pharmaceutical combination of claim 1 to the subject, thereby treating cancer in the subject.

17 . The method of claim 16 , wherein said antibody is a humanized antibody.

18 . The method of claim 17 , wherein said antibody comprises one or more complementarity-determining regions having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 and 81.

19 . The method of claim 18 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 13, 81 and 15, and said light chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 16, 17, and 18.

20 . The method of claim 18 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 25, 26, and 27, and wherein said light chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 28, 29, and 30.

21 . The method of claim 18 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has an amino acid sequence represented by SEQ ID NO: 66, and wherein said light chain has an amino acid sequence selected from the group consisting of SEQ ID NOS: 62 and 64.

22 . The method of claim 18 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has an amino acid sequence represented by SEQ ID NO: 72, and wherein said light chain has an amino acid sequence selected from the group consisting of SEQ ID NOS: 68 and 70.

23 . The method of claim 18 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has at least about 90% sequence homology with an amino acid sequence represented by SEQ ID NO: 66, and wherein said light chain has at least 90% sequence homology with an amino acid sequence selected from the group consisting of SEQ ID NOS: 62 and 64.

24 . The method of claim 18 , wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain has at least about 90% sequence homology with an amino acid sequence represented by SEQ ID NO: 72, and wherein said light chain has at least about 90% sequence homology with an amino acid sequence selected from the group consisting of SEQ ID NOS: 68 and 70.

25 . The method of claim 18 , wherein said antibody comprises the CDRs of an antibody produced by a hybridoma cell line having a deposit number selected from the group consisting of PTA-7667, PTA-7669, PTA-7670, PTA-7666, PTA-7668 and PTA-7671.